144 related articles for article (PubMed ID: 35106666)
1. Prognostic Significance of mRNA Expression RBBP8 or Its Methylation in Gliomas.
Liu Z; Cheng X; Lin S; Han Z; Jin H; Luan Z; Li P; Liang W; Qian R; Gao Y
Cell Mol Neurobiol; 2023 Jan; 43(1):409-422. PubMed ID: 35106666
[TBL] [Abstract][Full Text] [Related]
2. CKS2 (CDC28 protein kinase regulatory subunit 2) is a prognostic biomarker in lower grade glioma: a study based on bioinformatic analysis and immunohistochemistry.
Hu M; Li Z; Qiu J; Zhang R; Feng J; Hu G; Ren J
Bioengineered; 2021 Dec; 12(1):5996-6009. PubMed ID: 34494924
[TBL] [Abstract][Full Text] [Related]
3.
Qu S; Liu J; Wang H
Front Immunol; 2021; 12():648416. PubMed ID: 33889156
[TBL] [Abstract][Full Text] [Related]
4. MELK is a prognostic biomarker and correlated with immune infiltration in glioma.
Yang H; Zhou H; Wang G; Tian L; Li H; Zhang Y; Xue X
Front Neurol; 2022; 13():977180. PubMed ID: 36353126
[TBL] [Abstract][Full Text] [Related]
5. Recurrence- and Malignant Progression-Associated Biomarkers in Low-Grade Gliomas and Their Roles in Immunotherapy.
Teng C; Zhu Y; Li Y; Dai L; Pan Z; Wanggou S; Li X
Front Immunol; 2022; 13():899710. PubMed ID: 35677036
[TBL] [Abstract][Full Text] [Related]
6. Molecular and clinical features of a potential immunotherapy target ELK3 in glioma.
Xu H; Zhang L; Gao J; Wang J; Wang Y; Xiao D; Chai S
Medicine (Baltimore); 2022 Jul; 101(30):e29544. PubMed ID: 35905257
[TBL] [Abstract][Full Text] [Related]
7. CLCF1 Is a Novel Potential Immune-Related Target With Predictive Value for Prognosis and Immunotherapy Response in Glioma.
Jiang Y; Ji Q; Long X; Wang P; Tu Z; Zhang X; Zhu X; Huang K; Li J
Front Immunol; 2022; 13():810832. PubMed ID: 35265072
[TBL] [Abstract][Full Text] [Related]
8. Impact of beta-2 microglobulin expression on the survival of glioma patients via modulating the tumor immune microenvironment.
Tang F; Zhao YH; Zhang Q; Wei W; Tian SF; Li C; Yao J; Wang ZF; Li ZQ
CNS Neurosci Ther; 2021 Aug; 27(8):951-962. PubMed ID: 33960680
[TBL] [Abstract][Full Text] [Related]
9. Identification of Critical m
Zheng J; Wang X; Qiu Y; Wang M; Yu H; Zhou Z; Wu Z; Jiang X
Biomed Res Int; 2021; 2021():9959212. PubMed ID: 34212046
[TBL] [Abstract][Full Text] [Related]
10. DNAJC10 correlates with tumor immune characteristics and predicts the prognosis of glioma patients.
Liu F; Tu Z; Liu J; Long X; Xiao B; Fang H; Huang K; Zhu X
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34988580
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis reveals that LTBR is a immune-related biomarker for glioma.
Tang Q; Yuan Y; Li L; Xu Y; Ji W; Xiao S; Han Y; Miao W; Cai J; You P; Chen M; Ding S; Li Z; Qi Z; Hou W; Luo H
Comput Biol Med; 2024 May; 174():108457. PubMed ID: 38599071
[TBL] [Abstract][Full Text] [Related]
12. High bone sialoprotein (BSP) expression correlates with increased tumor grade and predicts a poorer prognosis of high-grade glioma patients.
Xu T; Qin R; Zhou J; Yan Y; Lu Y; Zhang X; Fu D; Lv Z; Li W; Xia C; Hu G; Ding X; Chen J
PLoS One; 2012; 7(10):e48415. PubMed ID: 23119009
[TBL] [Abstract][Full Text] [Related]
13. Expression, methylation and prognostic feature of EMILIN2 in Low-Grade-Glioma.
Wang LC; Cui WY; Zhang Z; Tan ZL; Lv QL; Chen SH; Shen XL
Brain Res Bull; 2021 Oct; 175():26-36. PubMed ID: 34280481
[TBL] [Abstract][Full Text] [Related]
14. Effects of ESCO2 or its methylation on the prognosis, clinical characteristics, immune microenvironment, and pathogenesis of low-grade glioma.
Liu Z; Cheng X; Pang B; Wang S; Liu B; Cao C; Qian R; Liang W; Zhu Y; Li P; Gao Y
Int Immunopharmacol; 2022 Mar; 104():108399. PubMed ID: 35008004
[TBL] [Abstract][Full Text] [Related]
15. Predictive and prognostic value of TLR9 and NFKBIA gene expression as potential biomarkers for human glioma diagnosis.
Miyar A; Habibi I; Ebrahimi A; Mansourpour D; Mokarizadeh A; Rajabi A; Farshgar R; Eshaghzadeh M; Zamani-Ahmadmahmudi M; Nodushan SM
J Neurol Sci; 2016 Sep; 368():314-7. PubMed ID: 27538656
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of a nine-gene signature in glioma patients based on mRNA expression profiling.
Bao ZS; Li MY; Wang JY; Zhang CB; Wang HJ; Yan W; Liu YW; Zhang W; Chen L; Jiang T
CNS Neurosci Ther; 2014 Feb; 20(2):112-8. PubMed ID: 24279471
[TBL] [Abstract][Full Text] [Related]
17. High TRAF3IP3 Level Predicts Poor Prognosis of Patients with Gliomas.
Yang G; Tang S; Zhang J; Qin L
World Neurosurg; 2021 Apr; 148():e436-e449. PubMed ID: 33444836
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of CD44 is associated with a poor prognosis in grade II/III gliomas.
Hou C; Ishi Y; Motegi H; Okamoto M; Ou Y; Chen J; Yamaguchi S
J Neurooncol; 2019 Nov; 145(2):201-210. PubMed ID: 31506754
[TBL] [Abstract][Full Text] [Related]
19. Correlation of alteration of HLA-F expression and clinical characterization in 593 brain glioma samples.
Feng E; Liang T; Wang X; Du J; Tang K; Wang X; Wang F; You G
J Neuroinflammation; 2019 Feb; 16(1):33. PubMed ID: 30755240
[TBL] [Abstract][Full Text] [Related]
20. Combinations of four or more CpGs methylation present equivalent predictive value for MGMT expression and temozolomide therapeutic prognosis in gliomas.
Chai RC; Zhang KN; Liu YQ; Wu F; Zhao Z; Wang KY; Jiang T; Wang YZ
CNS Neurosci Ther; 2019 Mar; 25(3):314-322. PubMed ID: 30117294
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
